The oral cavity is a very rare site for metastases, it was described in a number of cancers e.g. lung, breast, colon and prostate cancers. Prostate cancer with oral metastasis is uncommon and accounts for less than 2% of oral malignancies. We report a case of buccal mucosa metastases from ca prostate primary, confirmed by histopathology and immunohistochemistry tests.

Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan. Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy. Result The peak prevalence of the patients was found in Aljazeera state, and the least in Algadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. 50% of patients had 1-2 months interval time before the cancer recurrence, 32.2% had 3-4 months and 17.8% had 5-6 months before the disease recurrence. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary. Conclusion Our findings suggested that, Aljazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

prostate-specific antigen (PSA) response and pain. According to this study we found that docetaxel has an effective role in the treatment of mCRPC patients with an optimal number of 6-8 cycles every 3 weeks and with a dose of 75 mg. ■ Conflict of interest statement None declared.

No abstract

Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan.Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy.Result The peak prevalence of the patients was found in Al-Gazeera state, and the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients the cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary.Conclusion Our findings suggested that, Al-Gazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.